OptiNose, Inc. (OPTN) Financial Statements (2024 and earlier)

Company Profile

Business Address 1020 STONY HILL ROAD
YARDLEY, PA 19067
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments94,244110,502144,156147,144201,011234,854
Cash and cash equivalents94,244110,502144,156147,144201,011234,854
Receivables33,93235,44923,39413,64324246
Inventory, net of allowances, customer advances and progress billings9,44311,8479,0423,4847,1322,013
Inventory9,44311,8479,0423,4847,1322,013
Other current assets 2,8652,5814,0603,6142,1831,254
Other undisclosed current assets   1752,289 
Total current assets:140,484160,379180,652168,060212,857238,167
Noncurrent Assets
Property, plant and equipment7951,3472,0283,0523,8842,564
Other noncurrent assets2,9434,3456,1331,538248405
Total noncurrent assets:3,7385,6928,1614,5904,1322,969
TOTAL ASSETS:144,222166,071188,813172,650216,989241,136
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities48,18457,14150,06435,00425,53714,591
Accounts payable5,2918,0135,4893,6257,1165,893
Accrued liabilities42,89349,12844,57531,37918,4218,698
Debt128,575     
Deferred revenue and credits186
Contract with customer, liability160
Other liabilities1,9712,0942,1081,135  
Total current liabilities:178,73059,23552,17236,13925,69714,777
Noncurrent Liabilities
Long-term debt and lease obligation  126,418125,20274,92872,50071,863
Long-term debt, excluding current maturities  126,418125,20274,53172,50071,863
Liabilities, other than long-term debt1,2512,190    
Other liabilities6262,190    
Operating lease, liability 625  397
Other undisclosed noncurrent liabilities20,865 4,651 181 
Total noncurrent liabilities:22,116128,608129,85374,92872,68171,863
Total liabilities:200,846187,843182,025111,06798,37886,640
Equity
Equity, attributable to parent(56,624)(21,772)6,78861,583118,611154,496
Common stock1118253464138
Additional paid in capital628,242588,288534,585489,565436,554365,838
Accumulated other comprehensive loss(84)(81)(85)(48)(57)(111)
Accumulated deficit(684,893)(610,061)(527,765)(427,980)(317,927)(211,269)
Total equity:(56,624)(21,772)6,78861,583118,611154,496
TOTAL LIABILITIES AND EQUITY:144,222166,071188,813172,650216,989241,136

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues76,27674,65249,11734,6317,065162
Revenue, net162
Cost of revenue(9,263)(9,451)(7,520)(5,294)(1,588) 
Cost of goods and services sold(9,263)(9,151)(7,520)(5,294)(1,588) 
Gross profit:67,01365,20141,59729,3375,477162
Operating expenses(122,909)(131,651)(128,816)(124,938)(105,717)(48,530)
Other undisclosed operating loss      (162)
Operating loss:(55,896)(66,450)(87,219)(95,601)(100,240)(48,530)
Nonoperating income513524422,3262,405376
Investment income, nonoperating513524262,3592,453303
Gain (loss), foreign currency transaction, before tax  16(33)(48)73
Interest and debt expense(16,843)(15,973)(13,008)(16,778)(9,229)(910)
Other undisclosed income from continuing operations before equity method investments, income taxes     406162
Loss from continuing operations before equity method investments, income taxes:(72,226)(82,371)(99,785)(110,053)(106,658)(48,902)
Other undisclosed income (loss) from continuing operations before income taxes(2,607)75    
Loss from continuing operations:(74,833)(82,296)(99,785)(110,053)(106,658)(48,902)
Loss before gain (loss) on sale of properties:(82,296)(99,785)(110,053)(106,658)(48,902)
Net loss:(74,833)(82,296)(99,785)(110,053)(106,658)(48,902)
Other undisclosed net income attributable to parent      
Net loss attributable to parent:(74,833)(82,296)(99,785)(110,053)(106,658)(48,902)
Preferred stock dividends and other adjustments      (13,065)
Undistributed earnings (loss) allocated to participating securities, basic      
Net loss available to common stockholders, diluted:(74,833)(82,296)(99,785)(110,053)(106,658)(61,967)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(74,833)(82,296)(99,785)(110,053)(106,658)(48,902)
Comprehensive loss:(74,833)(82,296)(99,785)(110,053)(106,658)(48,902)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)4(37)954(12)
Comprehensive loss, net of tax, attributable to parent:(74,836)(82,292)(99,822)(110,044)(106,604)(48,914)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: